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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide
that is particularly refractory to chemotherapy. Several studies have proposed combination
chemotherapy regimen for HCC treatment. However, these therapies are not effective in
regressing tumor and prolonging survival of patient's suffering from HCC. Therefore, the
development of more effective therapeutic tools and new strategies for the treatment of HCC are
urgently needed. Over the last decade much attention has been focused on "bystander effect" as a
possible therapeutic strategy for the treatment of certain human tumors. Interest in this
therapeutic approach originated from numerous reports describing the radiation induced
bystander effect. However, the knowledge about chemotherapy induced bystander effect is still
limited. Hence, chemotherapy induced bystander phenomenon in hepatoma cells was explored by
utilizing Mitomycin C (MMC).
Results: MMC induced bystander killing was observed only in hepatoma cells and it did not occur
in cervical cancer cells. MMC induced bystander killing was transferable via medium. It occurred in
co-cultured cells indicating the involvement of secreted as well as membrane bound factors. FasL
and TRAIL were detected in the conditioned medium from treated cells. In medium transfer
experiment, pre-treatment with EDTA (a broad range protease inhibitor) diminished MMC
induced bystander killing. Following drug exposure, expression of Fas and TRAIL receptors
increased and treatment with neutralizing antibodies against FasL and TRAIL inhibited bystander
killing.
Conclusion: Our results highlight the therapeutic importance of MMC in the treatment of HCC
and implicate role of membrane bound and secreted forms of FasL and TRAIL in MMC induced
bystander killing.
Background
For solid tumors chemotherapy is characteristically the
choice of treatment other than surgical resection. How-
ever, there are inherent limitations associated with chem-
otherapy of solid tumors. These include toxicity to normal
cells, development of resistant cells within a tumor mass
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and inadequate delivery of cytotoxic drugs due to inacces-
sibility to certain cells within the same tumor mass. More-
over, the effectiveness of a chemotherapeutic drug is a
combined characteristic of the drug, tumor and patient.
The universal adoption of cancer chemotherapy is limited
by treatment complexities which make it mandatory to
explore drugs that, instead of assuring delivery to 100% of
tumor cells, utilize the ability of exposed cells to kill
neighboring unexposed tumor cells. Therefore, the con-
cept of "Bystander Effect" comes into the picture. The
name was initially borrowed from the field of gene ther-
apy, where it usually referred to the killing of several types
of tumor cells by targeting only one type of cell within a
mixed population [1]. Radiation induced bystander effect
has been extensively studied [2-4]. The available data con-
cerning this effect falls into two categories: (i) confluent
cultures where physical contacts between irradiated and
non-irradiated cells are made and where intercellular
communication is essential for the process and (ii)
sparsely populated cultures where the bystander effect
may be mediated by damage signals released into the cul-
ture medium by irradiated cells' [4-7].
Hepatocellular carcinoma (HCC) is one of the most com-
mon solid tumors that are particularly refractory to the
available chemotherapeutic drugs administered either
alone or in combination [8]. During the last few decades
many drugs have become available for treatment of a wide
variety of neoplastic diseases. Mitomycin C (MMC) is one
such drug used for treating solid tumors including hepa-
tocellular carcinoma and cervical cancer [9-12]. It is
already known that chemotherapeutic DNA-alkylating
agents can induce in vivo and in vitro paracrine factors that
cause growth inhibition. In most cases there is production
of soluble factors which have a distal effect on untreated
cells [13]. Moreover, single acute exposure of MMC has
been implicated in the changes in genomic stability of
exposed cells that signals the unexposed bystander cells to
respond similarly [14]. Various molecules that are
involved in the genesis of bystander effect remain uniden-
tified. There are reports demonstrating involvement of
reactive oxygen species, nitric oxide and cytokines such as
TGF  that promote bystander cell killing in sparsely pop-
ulated cell cultures [15,16].
HCCs are heterogeneous tumors. They commonly emerge
on the histological background of chronic liver disease.
Heterogeneity of a tumor occurs due to clonal variations
within a tumor mass during its development. However, in
spite of heterogeneity, there are certain common molecu-
lar alterations in all sub-clones within a tumor that corre-
lates with the monoclonal origin or homogeneity of a
tumor. These molecular alterations and signaling path-
ways play a crucial role in development of HCC and also
can be explored to develop an effective therapeutic tool
for treatment of HCC [17].
Our study reveals the mechanism of bystander killing by
MMC in hepatoma cells. We have earlier reported that 5-
fluorouracil induces bystander killing in mixed co-cul-
tures of breast cancer cells, a heterogeneous cell model
[18]. In the present work we addressed the ability of MMC
to specifically induce bystander killing of hepatoma cells
in both homogeneous and heterogeneous cell models. We
investigated the involvement of death ligands in the
bystander killing of hepatoma cells. Interestingly, MMC
induced bystander killing was transferable through
medium and it occurred also in co-cultured cells, impli-
cating the involvement of soluble as well as membrane
bound death effector molecules.
Methods
Cell lines and reagents
Hepatoma cell lines HepG2, Hep3B and cervical cancer
cell lines HeLa, SiHa were obtained from American Type
Culture Collection (Manassas, VA, USA) and maintained
in our in-house National Cell Repository. Cells were rou-
tinely cultured in minimum essential medium (MEM)
supplemented with 10% heat inactivated fetal bovine
serum (Sigma, MO, USA), penicillin (100 U/ml) and
streptomycin (100 g/ml) (Invitrogen Corporation, CA,
USA) at 37°C with 5% CO2. Chemotherapeutic drug
Mitomycin C (MMC), purchased from Sigma was dis-
solved in methanol to make a stock solution of 5 mM.
Methylethiazole tetrazolium (MTT) (USB, OH, USA) was
reconstituted in DMEM without phenol red to make 1
mg/ml working solution. Antibodies against Fas, FasL,
TRAIL, DR4, caspase-3, BID, PARP, -actin, recombinant
human FasL, HRP conjugated and FITC-conjugated sec-
ondary antibodies were purchased from Santa Cruz Bio-
technology (CA, USA). Neutralizing antibodies against
FasL and TRAIL (BD Biosciences, CA, USA) were reconsti-
tuted in sterile PBS to make 1 mg/ml solution.
Development of EGFP expressing cell lines
The cell lines, expressing enhanced green fluorescent pro-
tein (EGFP) were established by transfecting HepG2,
HeLa and SiHa cells with pEGFPN1 plasmid (Clontech,
CA, USA) by Lipofectamine 2000 (Invitrogen Corpora-
tion, CA, USA) as described in the manufacturer's proto-
col and selected on G418 (USB, OH, USA) 800 g/ml (for
HepG2) and 400 g/ml (for HeLa and SiHa cells). These
cells were subsequently maintained in medium contain-
ing G418 (100 g/ml).
Cell growth and cytotoxicity assay for HepG2 and HepG2-
EGFP cell lines
Cells were seeded in a 96 well plate and the growth kinet-
ics was performed as described previously [19]. To assayMolecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
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cytotoxicity of drug, cells seeded in a 96 well plate were
treated with indicated concentration of MMC for 48 h and
then cultured for additional 24 h in drug free medium.
Subsequently, MTT assay was performed as described pre-
viously [20].
Bystander cytotoxicity
In vitro co-culture experiments were designed to evaluate
whether the cytotoxicity induced by MMC in HepG2,
Hep3B, HeLa and SiHa cells (MMC treated cells were
termed as "Effector Cells") causes death in co-plated
bystander HepG2-EGFP, HeLa-EGFP and SiHa-EGFP cells
(EGFP expressing bystander cells which were not treated
with MMC were termed as "Target Cells"). Death of target
cells was evaluated by quantification of total live GFP flu-
orescence by exciting at 485 nm and measuring emission
at 510 nm (Fluoroskan Ascent FL, Labsystems, Finland).
Briefly, effector cells were plated and treated with MMC.
Target cells were co-plated and bystander cytotoxicity was
measured as described previously [18]. Wherever medium
transfer experiments were performed, the medium was
supplemented with 0.2% FBS to avoid cell death due to
growth factor depletion.
MTT assay to evaluate bystander cytotoxicity in co-
cultures containing effector and target Hep3B cells
Effector Hep3B cells were plated (3.5 × 103 and 7.5 × 103
cells per well) in a 96 well plate and allowed to adhere for
24 h at 37°C. Cells were treated with MMC for 24 h. Sub-
sequently, effector cells were washed twice with medium
and target Hep3B cells (7.5 × 103 cells per well) were co-
plated. After 72 h medium was decanted and MTT assay
was performed.
Trypan blue dye exclusion assay to detect involvement of 
TRAIL in mediating MMC induced bystander effect in co-
cultures containing effector and target Hep3B cells
Hep3B cells (2 × 105 cells per well) were plated in a six
well plate and allowed to adhere for 24 h at 37°C. Cells
were treated with MMC for 24 h. Thereafter, effector cells
were washed twice with medium and target Hep3B cells (2
× 105 cells per well) were co-plated with or without neu-
tralizing anti-TRAIL antibody. After 72 h of growth in co-
culture, trypan blue dye exclusion assay was performed as
described previously [20].
Conditioned medium collection and sandwich ELISA for 
detection of secreted FasL and TRAIL from effector cells
Secreted FasL and TRAIL were detected in conditioned
medium (CM) by sandwich ELISA. To obtain CM, 7 × 105
effector cells were plated in 60 mm tissue culture dishes
and kept overnight for adherence. Cells were treated with
MMC (150 nM) for 24 h. Wherever EDTA was used, cells
were pre-treated with 2 M EDTA for 1 h and MMC treat-
ment was given in the presence of EDTA for 24 h. Subse-
quently, medium was decanted, cells were washed twice
with medium and phenol-red free DMEM without FBS
was added to the cells. Cells were cultured for additional
24 h, 48 h, 72 h and 96 h. After each time period CM was
collected, centrifuged at 50,000 × g for 30 min and super-
natants were concentrated to half of the original volume
by SpeedVac (Thermo Savant, USA). For ELISA, each well
of micro-titre plate was coated with 50 l of anti-FasL Mab
and/or anti-TRAIL Mab (250 ng/50 l) for 3 h at 37°C,
followed by blocking of free sites with 100 l of blocking
reagent (5% BSA in PBS) for 2 h at 37°C. Test samples (50
l) were added and incubated for 3 h at 37°C followed by
incubation with 50 l of second anti-FasL and/or anti-
TRAIL polyclonal antibody, for 3 h at 37°C. After that, sec-
ondary HRP conjugated antibody was added in each well.
Finally, ABTS in 0.1 M Na-citrate buffer (pH 4.0) was
added to each well and incubated for 10 min at room tem-
perature before taking absorbance at 405 nm. Five washes
with PBS containing 0.05% Tween-20 were performed
between each step and plates were pat dried.
Western blot analysis and immunostaining
Whole cell lysates were made and western blotting was
performed as described previously [18]. For immunos-
taining, cells were fixed, permeabilized and immunofluo-
rescence was performed as described earlier [19].
Bystander cell killing in soft-agarose colony formation 
assay
Base agarose layer (1%) was made in a tissue culture plate
and a top agarose layer (0.8%) containing HepG2 cell was
added over the base layer. Consequently, plates were kept
in incubator and cells were allowed to grow inside the
semisolid agarose containing culture medium. After 4
weeks when sizable colonies appeared, a center well was
made in plates with the help of micropipette tip in which
untreated cells were added in control plate and treated
cells were added in the experimental plate. These wells
were covered with 0.8% agarose. The plates were incu-
bated for additional 4-5 weeks. After that colonies in both
plates were counted manually under microscope and pic-
tures were taken. The mean diameter of colonies was cal-
culated using ImagePro Plus 5.0 software
(MediaCybernetics, Silver Spring, MD, USA). Data thus
obtained on number of colonies and size of colonies was
depicted by graph.
Detection of apoptosis in effector and target cells by 
TUNEL assay
TdT mediated dUTP Nick End Labeling (TUNEL) assay
was performed by using APO-DIRECT (BD Biosciences,
CA, USA) and/or by In-situ cell death detection kit (Roche
Applied Science, PA, USA) following the manufacturer's
protocol. Briefly, HepG2 and Hep3B cells (7 × 103) were
seeded in multi-well slides (MP Biomedicals, OH, USA).Molecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
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For effector cells, MMC treatment was given for 24 h with
the indicated concentration. Thereafter, drug containing
medium was decanted and fresh medium without MMC
was added to each well. Cells were cultured in drug free
medium for additional 72 h. In case of target cells
medium transfer experiment was performed. Effector cells
(5 × 104) were plated in a 35 mm tissue culture dish and
treated with indicated concentration of MMC for 24 h.
Following treatment the effector cells were washed twice
with medium and fresh medium without drug was added
to the cells and incubated for additional 48 h. The
medium thus obtained was utilized to culture target cells
for 48 h before performing TUNEL assay. The medium
was supplemented with 0.2% FBS to avoid growth factor
depletion. For TUNEL assay cells were washed with PBS
and fixed with 3.7% paraformaldehyde, permeabilized
with 0.1% Triton X-100 and reaction mixture containing
TdT enzyme, FITC labeled dUTP was added to cells. The
reaction was performed at 37°C for 1 h. Cells were then
washed with rinsing buffer, PI solution was added to each
well and kept at 37°C for 30 min. After washing cells thor-
oughly they were overlaid with mounting medium con-
taining antifade (Santa Cruz Biotechnology, CA, USA).
The slides were subjected to confocal microscopy (Zeiss
LSM510, Heidelberg, Germany). Images were processed
by Adobe Photoshop software. Wherever In-situ cell death
detection kit was used to detect apoptosis, PI (50 g/ml)
was added to the cells and incubated at 37°C for 30 min
before they were overlaid with mounting medium.
Statistical analysis
The data were calculated with sigma plot 10 and values are
presented as arithmetic mean ± standard deviation (mean
± s.d). Unpaired student's t-test was used to determine the
statistical significance of differences between samples and
p-value < 0.05 were considered significant. * is for p-value
< 0.05, ** is for p-value < 0.005 and *** is for p-value <
0.0005.
Results
Growth pattern and chemosensitivity of EGFP expressing 
cells was similar to their corresponding parental cells
To investigate the growth properties and chemosensitivity
of parental and EGFP expressing cells, we performed an
MTT assay. Growth pattern of HepG2 and HepG2-EGFP
cells were similar (Fig. 1A). Both HepG2 and HepG2
EGFP cells were equally sensitive to MMC treatment (Fig.
1B). EGFP expressing HeLa and SiHa cells were also found
to be similar to parental cells in their growth pattern as
well as chemosensitivity towards MMC (Fig. 2 panel A to
D).
MMC induced bystander cytotoxicity in hepatoma cells is 
proportional to drug dosage
In vitro co-culture experiments were performed to investi-
gate the induction of bystander effect in hepatoma cells.
Briefly, effector cells were treated with MMC and thereaf-
ter target cells were co-plated. MMC treated HepG2 and
Hep3B cells induced bystander killing of unexposed cells
as determined by measuring total live fluorescence of
HepG2-EGFP in the target cells (Fig. 3A and Fig. 3B).
MMC treated Hep3B cells also induced bystander killing
in unexposed Hep3B cells as determined by measuring
cell survival by MTT (Fig. 3C). The bystander killing of tar-
get cells was directly proportional to the drug dose with
which the effector cells were treated. The cell survival
decreased with increasing concentration of MMC.
Bystander cytotoxicity is not observed in co-cultured 
cervical cancer cells treated with MMC
In an attempt to determine does MMC also cause
bystander effect in other solid tumor cells, HeLa and SiHa
effector cells were treated with MMC and corresponding
target cells stably expressing EGFP were co-plated.
Though, MMC per se was toxic to cervical cancer cells, no
cell killing by bystander effect was observed, as deter-
mined by measuring total live fluorescence (Fig. 4A) and
also as depicted in fluorescent photomicrographs (Fig.
4B).
MMC induced bystander effect is transferable through 
medium and extent of killing depends upon the number of 
effector cells
To investigate whether soluble toxic factors are involved
in killing of target cells by bystander effect, we performed
medium transfer experiments. Medium collected from
cells treated with MMC for different time duration was
used for culturing untreated HepG2-EGFP cells. After 48
h, total live fluorescence was quantified as mentioned in
materials and methods. The fluorescence intensity signifi-
cantly decreased in cells cultured in medium obtained
from MMC treated cells. The decrease in fluorescence
intensity was proportional to the time after which
medium was collected from the MMC treated cells. More-
over, there was an increase in fluorescence intensity when
neutralizing anti-FasL antibody was added in the medium
transferred onto the target cells at 96 h time point (Fig.
5A). Furthermore, bystander killing also increased with an
increase in the ratio of effector to target cells and maxi-
mum cell death was observed when this ratio was one
(Fig. 5B).
Both membrane bound and secreted form of death ligands 
are involved in MMC induced bystander effect
To explore the involvement of death ligands as a facilita-
tor of cell killing by bystander effect, we utilized neutral-
izing antibodies against FasL and TRAIL and also detectedMolecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
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the presence of secreted forms of FasL and TRAIL in CM by
sandwich ELISA. It is already reported that chemothera-
peutic drugs up- regulate the expression of FasL and TRAIL
[21] and in several studies the involvement of these death
ligands in bystander effect has been reported [18,22-24].
When the EGFP expressing target HepG2 cells were co-
plated with MMC treated effector cells (HepG2 and
Hep3B) in the presence of neutralizing anti-FasL anti-
body, the EGFP intensity of target cells was similar to that
of cells co-plated with untreated cells. Under similar
experimental conditions, when neutralizing anti-TRAIL
antibody was utilized, no significant change in the EGFP
Cell growth and cytotoxicity assay in HepG2 and HepG2-EGFP cell lines Figure 1
Cell growth and cytotoxicity assay in HepG2 and HepG2-EGFP cell lines. (A) Growth kinetics of HepG2 and 
HepG2-EGFP cells shows no significant alteration in growth properties. HepG2 and HepG2-EGFP cells (2 × 103) were seeded 
in a 96 well plate and subsequently cultured for 24 h, 48 h, 72 h and 96 h, and MTT assay was performed. Absorbance was 
measured at 570 nm using 630 nm as reference filter. Optical density of 0.2 corresponds to 2 × 103 cells. (B) MMC is equally 
cytotoxic to HepG2 and HepG2-EGFP cells. HepG2 and HepG2-EGFP cells (1 × 104) were seeded in a 96 well plate and kept 
overnight for adherence. MMC treatment with indicated concentrations was given for 48 h. Cells were grown in a drug free 
medium for 24 h before performing the MTT assay. Data presented are representative of three independent experiments per-
formed in triplicates and expressed as mean ± s.d.Molecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
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intensity of target cells was observed. On the other hand,
in mixed co-cultures of effector Hep3B and target HepG2-
EGFP in the presence of neutralizing anti-TRAIL antibody,
cell survival was not altered, whereas in the presence of
neutralizing anti-FasL antibody the cell survival increased
significantly (Fig. 5C). In co-cultures containing effector
Hep3B and target Hep3B cells in the presence of neutral-
izing anti-TRAIL antibody, cell survival increased in com-
parison to cells which were not incubated with the
antibody, as determined by measuring percentage cell via-
bility by trypan blue exclusion assay (Fig. 5D). The pres-
ence of the secreted form of these ligands in CM of MMC
treated cells was detected by sandwich ELISA. There was a
significant increase in FasL in CM obtained from treated
HepG2 cells as compared to CM from control cells taken
at identical time points. Unlike in HepG2 cells, there was
significant increase in FasL and TRAIL in CM obtained
from treated Hep3B cells in comparison to CM from con-
trol cells taken at identical time points (Fig. 6A and 6B).
The levels of secreted ligands increased up to 96 h follow-
ing MMC treatment. The amount of FasL released from
treated HepG2 cells was in the range of 1.4 g/ml to 1.6
Cell growth and cytotoxicity assay for HeLa/HeLa-EGFP cells and for SiHa/SiHa-EGFP cells Figure 2
Cell growth and cytotoxicity assay for HeLa/HeLa-EGFP cells and for SiHa/SiHa-EGFP cells. Cells (2 × 103) were 
seeded in a 96 well plate and subsequently cultured for 24 h, 48 h, 72 h and 96 h and MTT assay was performed. Absorbance 
was measured at 570 nm using 630 nm as reference filter. Optical density of 0.2 corresponds to 2 × 103 cells. (A) Growth 
kinetics of HeLa and HeLa-EGFP cells. (B) Growth kinetics of SiHa and SiHa-EGFP cells. (C) MMC cytotoxicity on HeLa and 
HeLa-EGFP cells. (D) MMC cytotoxicity on SiHa and SiHa-EGFP cells. Cytotoxicity assay for HeLa, HeLa-EGFP, SiHa and SiHa-
EGFP was performed as done for HepG2 and HepG2-EGFP. Data presented are representative of three independent experi-
ments performed in triplicates and expressed as mean ± s.d.Molecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
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g/ml from 7 × 105 cells, which was significantly more
than the amount of TRAIL released (0.15 g/ml to 0.36
g/ml). The amount of TRAIL released by 7 × 105 Hep3B
cells ranged between 0.18 g/ml to 0.54 g/ml. Finally,
the involvement of FasL and TRAIL was confirmed by uti-
lizing respective neutralizing antibodies, as shown in flu-
orescent photomicrographs of HepG2 cells (Fig. 6C) and
Hep3B cells (Fig. 6D). Collectively, these results indicate
the involvement of FasL in transferring cytotoxicity in
HepG2 cells. In Hep3B cells, though MMC treatment
Co-culture experiments to evaluate MMC induced bystander killing Figure 3
Co-culture experiments to evaluate MMC induced bystander killing. (A) Bystander effect mediated by effector 
HepG2 cells treated with MMC (0.3 nM, 3 nM, 30 nM and 150 nM) for 24 h, towards target HepG2-EGFP cells. Effector cells 
were plated in a 12-well culture plate at a density of 5 × 104 cells per well and kept for adherence at 37°C for 24 h. MMC treat-
ment was given for 24 h, after that medium was decanted and cells were washed twice with medium. 5 × 104 target cells were 
co-plated and the co-cultures were allowed to grow at 37°C for 72 h. Subsequently cells were trypsinized and total live fluo-
rescence was quantified. In order to avoid any possibility of cell death due to residual drug in the well, we used an empty well 
containing no effector cells but only medium containing 150 nM MMC and subsequently this well was processed similarly 
before plating the target HepG2-EGFP cells. (B) Bystander effect mediated by effector Hep3B cells treated with MMC (30 nM 
and 150 nM) towards target HepG2-EGFP cells. (C) Bystander effect mediated by effector Hep3B cells towards target Hep3B 
cells. MTT assay was performed to evaluate bystander cytotoxicity in Hep3B cells. Cells were plated and treated with MMC 
(30 nM, 150 nM and 200 nM) for 24 h and target Hep3B cells were co-plated as described in materials and methods. After 72 h 
medium was decanted and 50 l MTT (1 mg/ml) was added in each well and incubated for 4 h at 37°C. Subsequently, formazan 
crystals were solubilized in 50 l of iso-propanol by incubating with shaking for 10 min, at room temperature. Absorbance was 
measured at 570 nm using 630 nm as reference filter. Data presented are representative of three independent experiments 
performed in triplicates and expressed as mean ± s.d. * and ** significantly differs from there respective controls.Molecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
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facilitated release of both FasL and TRAIL, due to reduced
expression of Fas in Hep3B [21], the secreted FasL did not
promote toxicity and instead secreted TRAIL was involved
in propagating bystander cell killing following MMC
treatment.
Expression of death receptors increases following MMC 
treatment
Drug treatment, in addition to facilitating an increase of
death ligands, has also been shown to enhance the expres-
sion of their cognate receptors on the cell membrane [25].
Therefore, to ascertain that MMC treatment also alters the
expression of death receptors, we examined the expres-
sion of Fas and TRAIL receptors after MMC treatment. It
was observed that the expression of Fas receptor increased
MMC fails to induce bystander killing in cervical cancer cell Figure 4
MMC fails to induce bystander killing in cervical cancer cell. (A) Effector HeLa and SiHa cells were plated and treated 
with MMC (200 nM and 500 nM respectively) for 24 h. EGFP expressing target HeLa and SiHa cells were co-plated and the co-
culture were allowed to grow for 72 h after that cells were trypsinized and total live fluorescence was quantified. Data pre-
sented are representative of three independent experiments and are expressed as mean+s.d. of triplicate samples. (B) Fluores-
cent photomicrographs of co-cultured cells to evaluate MMC induced bystander killing: (a) untreated HeLa cells co-plated with 
HeLa-EGFP, (b) MMC treated HeLa cells (200 nM) co-plated with HeLa-EGFP, (c) untreated SiHa cells co-plated SiHa-EGFP, 
(e) MMC treated SiHa cells (500 nM) co-plated with SiHa-EGFP.Molecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
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Medium transfer experiments to detect the presence of soluble cytotoxic effector molecules Figure 5
Medium transfer experiments to detect the presence of soluble cytotoxic effector molecules. (A) Time-course 
release of cytotoxic factor from MMC treated effector HepG2 cells. The effector cells were treated with MMC for 24 h and 
fresh medium was added as described in materials and methods. At the time indicated, corresponding supernatants were col-
lected and added to the untreated target HepG2-EGFP cells with or without neutralizing anti-FasL antibody. Target cells were 
incubated with the supernatants for 48 h before quantitating fluorescence. The supernatants were supplemented with 0.2% FBS 
to avoid cell death due to growth factor depletion. The culture supernatant from untreated HepG2 cells was used as control 
and fluorescent intensity was calculated with respect to identical time point controls. (B) The target cell death increases with 
the increase in number of effector cells. Effector cells were treated with MMC for 24 h and fresh medium was added as 
described in materials and methods. The supernatants were collected after 48 h and used to culture target HepG2-EGFP cells 
for 48 h before quantitating fluorescence. (C) Involvement of death ligands in bystander killing of hepatoma cells. Bystander kill-
ing of HepG2-EGFP cells is mediated by FasL. Effector HepG2 and Hep3B cells were treated with MMC (150 nM) and target 
HepG2-EGFP cells were co-plated with or without neutralizing antibody against FasL (1 g/ml) and TRAIL (2 g/ml). (D) 
Bystander killing of target Hep3B cells by effector Hep3B cells treated with MMC (150 nM) is mediated by TRAIL. Trypan blue 
assay to detect the percentage cell viability in co-cultures of effector and target Hep3B cells in the presence of neutralizing anti-
TRAIL antibody. After 72 h of growth in co-culture cells were harvested by trypsinization and stained with 0.005% trypan blue 
for 5 min at RT. Unstained as well as stained cells were counted in haemocytometer and percentage cell viability was calcu-
lated. Data presented are representative of three independent experiments performed in triplicates and expressed as mean ± 
s.d. *, ** and *** differs significantly at p < 0.05.Molecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
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in HepG2 cells, but no change in TRAIL receptor DR4 was
detected (Figure 7A). The expression of TRAIL receptor
DR4 increased significantly in Hep3B cells, but no
changes in Fas receptor were observed (Figure 7C). These
results are also supported by confocal laser scanning
images of the cells (Fig. 7B and 7D).
Treatment with EDTA decreases bystander cytotoxicity
The involvement of secreted death ligands in MMC
induced bystander effect was further confirmed by utiliz-
ing EDTA, a broad range protease inhibitor. EDTA inhibits
the cleavage of FasL from its membrane [26]. In the pres-
ence of EDTA, bystander killing of target cells decreased as
Sandwich ELISA to detect secreted form of death ligands in conditioned medium obtained from MMC treated hepatoma cells Figure 6
Sandwich ELISA to detect secreted form of death ligands in conditioned medium obtained from MMC treated 
hepatoma cells. (A) Sandwich ELISA for quantification of secreted FasL from untreated and treated HepG2 and Hep3B cells 
at different time points. (B) Sandwich ELISA for quantification of secreted TRAIL from untreated and treated HepG2 and 
Hep3B cells at different time points. Data presented are representative of three independent experiments performed in tripli-
cates expressed as mean ± s.d. *** differs significantly from the respective control. (C) Fluorescent photomicrographs of co-
cultured cells to evaluate MMC induced bystander killing of HepG2-EGFP cells: (a) untreated effector HepG2 cells, (b) effector 
cells treated with MMC (150 nM), (c) neutralizing anti-FasL antibody (1 g/ml), (d) neutralizing anti-TRAIL antibody (2 g/ml). 
(D) Photomicrographs of co-culture of effector and target Hep3B cells: (a) untreated effector Hep3B cells with target Hep3B 
cells, (b) MMC (150 nM) treated effector Hep3B cells with target Hep3B cells, (c) effector Hep3B cells treated with MMC and 
target Hep3B cells co-plated in the presence of neutralizing anti-TRAIL antibody (2 g/ml), (d) effector Hep3B cells pretreated 
with EDTA (2 M) followed by MMC treatment and then target Hep3B cells were co-plated.Molecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
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evident by an increase in total live fluorescence (Fig. 8A)
and also as shown in fluorescent photomicrographs of
HepG2 cells (Fig. 8B) and Hep3B cells (Fig. 6D panel a, b
and d). Furthermore, to verify whether EDTA treatment
caused a decrease in release of secreted FasL from MMC
treated HepG2 cells, we performed sandwich ELISA in CM
obtained from treated effector HepG2 cells and the cells
pre-treated with EDTA followed by MMC treatment. There
was a significant decrease in the quantity of FasL released
from the cells pre-treated with EDTA followed by MMC
treatment as compared to only MMC treated cells (Fig.
8C). This result was also supported by western blot analy-
Expression of death receptors increases after MMC treatment in hepatoma cells Figure 7
Expression of death receptors increases after MMC treatment in hepatoma cells. HepG2 and Hep3B cells were 
treated with MMC for 24 h. Cells were washed twice with medium, fresh medium without MMC was added and cells were 
incubated again for 24 h at 37°C. After post-treatment growth in MMC free medium whole cell lysate was prepared and west-
ern blot was performed. (A) Western blot analysis: lane (1) control HepG2 cells, lane (2) HepG2 treated for 24 h with MMC 
and lane (3) HepG2 treated for 24 h with MMC followed by post treatment growth in drug free medium for 24 h. -actin was 
detected as a loading control. Where ever required, blots were stripped by incubating the membranes at 50°C for 30 min in 
stripping buffer (62.5 mM Tris-Cl pH 6.7, 100 mM mercaptoethanol, 2% SDS) with intermittent shaking. Membranes were 
washed thoroughly with TBS and reprobed with required antibodies. Otherwise gels run in duplicates were probed for the 
desired proteins by western blotting. (B) Immunofluorescence staining of HepG2 cells. Cells were treated with MMC for 24 h, 
washed twice with medium and fresh medium without MMC was added and cultured for 24 h. Cells were fixed with 4% para-
formaldehyde, permeabilized with 1% Triton X- 100 and blocked with 5% FBS. Cells were then incubated with anti-FasL, anti-
Fas, anti-TRAIL and anti-DR4 primary antibodies for 2 h and subsequently stained with FITC conjugated secondary antibody for 
1 h.Molecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
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sis of CM from MMC treated HepG2 cells as well as from
cells pre-treated with EDTA followed by MMC treatment
(Additional file 1). To determine whether the cytotoxicity
mediated by MMC was due to induction of apoptosis, we
detected PARP cleavage by western blotting in co-cultures
containing MMC treated effector HepG2 cells co-plated
with target HepG2-EGFP cells, in the presence and
absence of EDTA. PARP cleavage decreased in MMC
treated cells pre-exposed to EDTA (Fig. 8D).
Both effector and target cells undergo apoptosis following 
MMC treatment
We examined the expression of apoptosis related mole-
cules in both HepG2 and Hep3B cells after MMC treat-
Secreted form of FasL involved in mediating bystander cytotoxicity and apoptosis in HepG2 cells Figure 8
Secreted form of FasL involved in mediating bystander cytotoxicity and apoptosis in HepG2 cells. (A) Effector 
HepG2 cells were pretreated with EDTA (2 M) for 1 h and MMC was added in the same medium containing EDTA. Subse-
quently, this medium was used to culture target HepG2-EGFP cells and fluorescent intensity was measured after 48 h. (B) Flu-
orescent photomicrograph: (a) untreated HepG2 effector cells co-plated with target HepG2-EGFP cells and (b) effector 
HepG2 cells pretreated with 2 M EDTA followed by MMC treatment for 24 h. (C) Sandwich ELISA to detect FasL in CM from 
MMC treated and cells pretreated with EDTA followed by MMC treatment for 24 h. Data presented are representative of 
three independent experiments performed in triplicates and expressed as mean ± s.d. ** differs significantly at p < 0.005. (D) 
Effector HepG2 cells treated with MMC for 24 h as well as from effector HepG2 cells pretreated with EDTA for 1 h followed 
by MMC treatment for 24 h. Cells were then washed twice with medium, target HepG2-EGFP cells were co-plated and the co-
culture were grown for 72 h, and whole cell lysates were made from the co-culture to perform western blot analysis. The lev-
els of PARP p116 proform and its cleavage product p85 were detected. -actin was detected as a loading control. Lane (1) 
untreated effector HepG2 cells. (2) MMC treated effector cell and harvested after 24 h. (3) MMC treated effector cells and 
harvested after 48 h. (4) EDTA (2 M) pre-treatment followed by MMC treatment of effector cells and harvested after 24 h. 
(5) EDTA (2 M) pre-treatment followed by MMC treatment of effector cells and harvested after 48 h.Molecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
Page 13 of 19
(page number not for citation purposes)
MMC induced apoptotic factors Figure 9
MMC induced apoptotic factors. (A) HepG2 and Hep3B cells treated with MMC were harvested and cell lysates were pre-
pared. The expression of apoptosis related proteins were dectected by western blot analysis. The protein levels of PARP p116 
proform and its p85 cleavage product, pro caspase-3 p32 and its cleavage product p11, and BID p21 proform were detected. 
Lane (1) untreated cells, (2) cells treated with MMC for 24 h and (3) cells treated with MMC for 24 h followed by post treat-
ment growth in MMC free medium for 24 h. -actin was detected as a as loading control. Where ever possible blots were 
stripped and reprobed with required antibodies. Otherwise gels run in duplicates were probed for the desired proteins by 
western blotting. (B) TUNEL assay for effector and target cells. For effector cells, HepG2 and Hep3B cells were treated with 
MMC (150 nM) for 24 h. Then the cells were washed with medium and cultured for additional 72 h before performing TUNEL 
assay. Similarly, for target cells, medium form untreated as well as from treated HepG2 or Hep3B cells were used to culture 
target HepG2 and Hep3B cells respectively for 48 h before performing TUNEL assay. The medium was supplemented with 
0.2% FBS to avoid growth factor depletion.Molecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
Page 14 of 19
(page number not for citation purposes)
ment. Decreased expression of PARP p116, pro caspase-3,
BID and increased levels of caspase-3 was observed in
MMC treated cells (Fig. 9A). This observation was further
supported by TUNEL assays in which HepG2 and Hep3B
cells were treated with MMC for 24 h and then cultured in
drug free medium for an additional 72 h. Also, the effect
on the target cells was investigated by transferring CM
from the treated effector cells and incubating them for 48
h before performing a TUNEL assay. Results from all of
these experiments clearly demonstrated that MMC
induced apoptosis directly in the effector cells and by
bystander effect in the target cells (Fig. 9B).
Death factors released by MMC treated cells significantly 
reduce the size of colonies in soft-agarose assay
Because the bystander cell killing was transferable via
medium, we designed a novel experimental strategy to
ascertain that this effect was also transferable through
solid medium. We took advantage of soft-agarose colony
formation assay in which cells not only grow as a mass to
mimic tumor, but also represent anchorage independent
growth of tumors. Death inducing soluble factors secreted
by the effector cells are likely to diffuse slowly over a
period of time. This diffusion of death signal, if effective,
would have an impact on either the number or size of col-
onies during the incubation period of 4 to 5 weeks after
seeding of effector cells. Interestingly, colony size of the
target cells in which untreated effector cells were seeded
and allowed to grow varied significantly in mean diame-
ter, most of them ranging between 50-80 m. On the
other hand, the colony size of the target cells in which
treated effector cells were seeded was reduced dramati-
cally, with most colonies ranging between 20-50 m.
Also, the number of colonies was significantly less as com-
pared to those in a plate containing untreated effector
cells (Fig. 10 and Fig. 11). Almost no colonies were
detected in plates in which pure recombinant FasL was
added in the centre well. When the treated HepG2 effector
cells together with a neutralizing anti-FasL antibody were
added in the center well, more colonies were detected
(Additional file 2C and 2D). This result was further sup-
ported by yet another colony formation assay in which
medium from untreated and/or treated effector HepG2
cells was added in the plates containing target HepG2 cells
in either the absence or presence of the neutralizing anti-
FasL antibody. The number of colonies present was very
low in the plates in which medium from treated effector
cells was added in comparison to the colonies present in
the plates in which medium from untreated cells or in
which medium supplemented with neutralizing anti-FasL
antibody was added (Additional file 3). These results
clearly demonstrate that MMC induced release of FasL is
able to propagate its effect at a distinct location.
Discussion
In the present study we addressed the efficacy of MMC in
hepatoma cells by exploiting its ability to promote
bystander killing in addition to its direct toxicity. Our
results from the co-culture experiments indicated that the
bystander signal initiated after 24 h of treatment, even at
a low dose of 0.3 nM MMC. Significant increase in
bystander killing was observed up to 72 h after drug treat-
ment which was dependant upon the number of effector
cells treated and on the MMC dosage used. MMC induced
bystander killing was cell type specific with no bystander
effect occurring in cervical cancer cells, although the drug
did induce direct cytotoxicity in these cells per se.
Chemotherapeutic drugs induce expression of death
receptors [21,27,28], and their role in drug induced
bystander effect is still not clear. MMC treatment
increased Fas expression in HepG2 cells and these cells
were sensitive to Fas/FasL mediated apoptosis [29,30].
Whereas, Hep3B cells are reported to be resistant to Fas
mediated apoptosis [21,31]. Our data clearly demon-
strated that Hep3B cells express Fas, though reduced per-
centage of cells displayed the expression and this
observation was in agreement with the report of Lambo-
ley et al [31]. Moreover, in MMC treated Hep3B cells, no
significant increase in the levels of Fas was detected.
Therefore, it is unlikely that the Fas-FasL pathway was
involved in MMC induced bystander effect in co-cultures
of effector Hep3B and target Hep3B cells. Concurrently,
MMC treatment caused a significant increase in TRAIL
receptor DR4 in Hep3B cells. In the presence of neutraliz-
ing anti-TRAIL antibody, the MMC induced bystander
killing of Hep3B diminished, indicating involvement of
the TRAIL pathway in mediating a bystander effect. Inter-
estingly, the presence of neutralizing anti-FasL antibody
prevented bystander killing in HepG2 cells, but cell death
was not prevented in the presence of neutralizing anti-
TRAIL antibody. In mixed co-cultures of effector Hep3B
cells and target HepG2-EGFP cells, there was also a
decrease in bystander killing in the presence of neutraliz-
ing anti-FasL antibody, suggesting involvement of the Fas-
FasL pathway. Additionally, the significant increase in
FasL and TRAIL in CM of MMC treated effector cells was
suggestive of involvement of secreted form of these lig-
ands being responsible for transferring a bystander signal
through the medium. The involvement of these ligands
was reconfirmed by culturing MMC treated effector cells
with/without neutralizing anti-FasL and/or anti-TRAIL
antibody in target HepG2 and Hep3B cells, respectively
(Additional file 4). The pro-apoptotic role of secreted
forms of FasL and TRAIL in hepatocellular carcinoma has
been reported [32-34], though there are contradictory
reports suggesting an anti-apoptotic role of secreted FasL
[35-37]. It has been reported that the cleaved product of
human FasL has cytotoxic activity [32], but it is relativelyMolecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
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weaker than the membrane associated FasL [38]. Also, the
cytotoxic activity is enhanced if the death ligands are
present in cross linked or aggregated form [32-35]. Thus,
the detection of the high molecular weight form of FasL (
48 kDa) in CM from treated HepG2 cells suggested its
involvement in bystander killing (Additional file 1). The
significance of secreted death ligands in bystander effect
was further confirmed by treatment with EDTA. As shown
in Fig. 8A, in the presence of EDTA, the bystander killing
decreased in medium transfer, as well as under co-cultur-
ing conditions (Fig. 8B). Treatment with EDTA led to a
decreased abundance of FasL in CM that correlated well
with diminished PARP cleavage in HepG2 cells co-cul-
tures (Fig. 8C and Fig. 8D) Although, HepG2 effector cells
also released TRAIL, the amount was insignificant in com-
parison to the amount of FasL released in the medium.
For a chemotherapeutic drug to be effective in eliminating
tumor completely, the drug or its effect should reach not
only the cells in periphery, but also the inner cellular mass
of the tumor. One of the possibilities to achieve this was
to explore the feasibility of diffusion of released cytotoxic
effector molecules from the tumor cells exposed to the
drug directly. Therefore, to verify that indeed released
Soft-agarose colony formation assays to evaluate the role of secreted FasL in mediating cytotoxic effect Figure 10
Soft-agarose colony formation assays to evaluate the role of secreted FasL in mediating cytotoxic effect. Base 
agarose layer was made in DMEM without phenol red and top agarose layer containing 4 × 103 HepG2 cells was poured over 
the base layer. After 4 weeks of growth in semisolid medium untreated and treated effector cells (5 × 105) were added in the 
center well of the plates. These plates were incubated at 37°C for 4 weeks. (A) Number of colonies decreased in the presence 
of effector cells treated with MMC as compared to control effector cells. The number of colonies decreased drastically in the 
presence of recombinant FasL (6 g) which served as a positive control. (B) Photomicrographs of soft-agarose plate containing 
MMC treated effector HepG2 cells. The colony size diminished and very small colonies (<20 m in mean diameter) were 
observed in the area surrounding center well containing treated effector cells. (C) Photomicrographs of soft-agarose colonies 
at 4× magnification and 10× magnification corresponding to different fields from the plate containing control effector cells and 
the plate containing MMC treated effector cells, in the center well.Molecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
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cytotoxic effector molecules from the treated cells were
able to diffuse through semisolid medium thereby mim-
icking in-vivo conditions, we performed soft-agarose col-
ony formation assays. Because MMC treated effector
HepG2 secret FasL, we hypothesized that this ligand
should diffuse through semisolid medium. Interestingly,
we found that in the plate in which treated HepG2 effector
cells were added in the centre well, colony size was
smaller and they were of distinct shapes, suggestive of
diminished cell growth (Fig. 11B). The decrease in size
and alterations in shape of colonies was prevented when
the treated effector cells were added in the centre well
along with neutralizing anti-FasL antibody (Additional
file 2d).
Conclusion
Our results support the idea that bystander killing in
hepatoma cells is mediated by membrane bound as well
as secreted form of death ligands. This is further assisted
by increased expression of corresponding death receptors.
Release of secreted cytotoxic factors diminishes considerably the size of soft-agarose colonies Figure 11
Release of secreted cytotoxic factors diminishes considerably the size of soft-agarose colonies. (A) Pie chart 
showing percentage distribution of colonies of different mean diameters (colonies >20 m in diameter were considered) in the 
soft-agaose plate containing untreated effector HepG2 cells and in the plate containing MMC treated effector HepG2 cells. (B) 
Photomicrographs of colonies at higher magnification showing diminished growth when MMC treated effector HepG2 cells 
were added in the center well of soft-agarose plate containing colonies of target cells.Molecular Cancer 2009, 8:87 http://www.molecular-cancer.com/content/8/1/87
Page 17 of 19
(page number not for citation purposes)
Moreover, since FasL upregulates Fas [39,40], we propose
that the release of the secreted form of the death ligand
from effector cells is able to boost the expression of death
receptors on bystander cells (Fig. 12). The work described
in this study suggests that MMC induces direct cytotoxicity
in cervical cancer and hepatoma cells. However, amplifi-
cation of killing is not achieved in cervical cancer cells
because death signals are not propagated by bystander
effect. Therefore, MMC may potentially be of more thera-
peutic value in treating hepatocellular carcinoma than cer-
vical cancers because of its ability to initiate bystander
effect. Generally, at early stages of tumor development the
cell population is likely to be homogeneous, whereas in
advanced stages it is likely to be heterogeneous. Since
MMC is able to induce bystander killing in both homoge-
neous and heterogeneous cellular models, it is likely to be
more effective in treatment forearly and advanced staged
HCCs.
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